Table 4.
Local histopathological diagnosis of consecutive Bethesda III/IV nodules with ALK, BRAF, NTRK, or RET fusions (other than CCDC6/RET [RET/PTC1] or NCOA4/RET [RET/PTC3]) with available local surgical pathology diagnoses
| Fusion kinase domain | Local histology |
|---|---|
|
ALK
n = 15 |
• PTC 33% |
| • Hyperplasia 27% | |
| • Follicular variant PTC 13% | |
| • Adenomatoid nodule 13% | |
| • Follicular thyroid cancer 7% | |
| • Unspecified thyroid malignancy 7% | |
|
BRAF
n = 17 |
• PTC 53% |
| • Follicular variant PTC 23% | |
| • Follicular adenoma 18% | |
| • NIFTP 6% | |
|
NTRK
n = 25 |
• PTC 56% |
| • Follicular variant PTC 40% | |
| • Hyperplasia 4% | |
|
RET (not CCDC6/RET or NCOA4/RET) n = 7 |
• PTC 57% |
| • Follicular variant PTC 29% | |
| • NIFTP 14% |
Abbreviations: NIFTP, noninvasive follicular thyroid neoplasm with papillary-like features; PTC, papillary thyroid cancer.